Our research studies are focusing on:
1. Phenotyping of patients with sellar/suprasellar disorders beyond hormone levels and identifying biomarkers for the diagnosis and prognosis of these disorders
Research study of pituitary tumors and related hypothalamic disorders
Under the protocol 97-CH-0076 (https://clinicaltrials.gov/ct2/show/NCT00001595) we are evaluating patients with pituitary disorders/adenomas/tumors. We are collecting clinical and biochemical data as well as research biospecimens to advance our knowledge on the genetic etiology, pathophysiology, presentation, diagnosis, and treatment of pituitary disorders.
Research study for survivors of pediatric Cushing disease
Dr Keil is leading a research protocol on the long-term effects of pediatric hypercortisolemia (19-CH-0051, https://clinicaltrials.gov/ct2/show/NCT03831958) to identify residual clinical and biochemical findings after cure of pediatric Cushing syndrome. Patients are eligible for the protocol if they diagnosed with ACTH-secreting pituitary adenomas (Cushing disease) before the age of 21 years old and are in biochemical remission. Patients are studies at 5-year intervals until 20 years after cure. Anthropometric, clinical, biochemical, imaging and other data are collected.
2. Identifying therapeutic approaches for patients with rare sellar/suprasellar disorders
Research study for children with growth hormone excess
Gigantism is a condition characterized by excessive growth hormone (GH) secretion, caused commonly by GH-secreting pituitary adenomas or other rare disorders of dysregulated GH secretion. Under the protocol 19-CH-0071 (https://clinicaltrials.gov/ct2/show/NCT03882034) we study the safety and efficacy of pegvisomant in children and adolescents with growth hormone excess.